Nordén Lillebil, Lidman Christer
Stockholm Addiction Centre, Karolinska University Hospital, Huddinge, Sweden.
Scand J Infect Dis. 2005;37(6-7):493-6. doi: 10.1080/00365540510036642.
Needle sharing is a risk factor for contracting blood-borne infections among injecting drug users (IDUs). We explored the relation of socio-financial, physical and mental health factors (ASI) to risk behaviour (Qr23) for contracting blood-borne infections among IDUs (Addiction Severity Index and Questionnaire for risk behaviour). 42 HIV negative IDUs were studied prospectively. The median age was 42.5 (range 18-61) y, 28 of 42 (67%) were males and median duration of injecting was 19.0 (range 0-43) y. HCV and HBV antibodies were found in 37 (88%) and 31 (71%) participants, respectively. Poly drug use was reported by 23 (55%) participants; amphetamine by 10 (24%) and heroin by 9 (21%). From the ASI data we were unable to find any statistically significant factor that was associated with needle sharing (n = 26/42, 61%) or sharing drug mixture/filter (n = 25/42, 59%). 19 (73%) of 26 participants who shared needles also shared drug mixture/filter. Of these 26 IDUs, 7 shared needles with partners, 11 with acquaintances, 3 with strangers and 5 with all categories. In conclusion, the study group showed differentiated risk behaviours for blood-borne infections with regard to various persons and to whom they were exposed. This suggests that IDUs may benefit from individualized counselling regarding risks for infections with HIV, HCV and HBV.
共用针头是注射吸毒者感染血源性感染的一个风险因素。我们探讨了社会经济、身心健康因素(成瘾严重程度指数)与注射吸毒者感染血源性感染的风险行为(问题23)之间的关系(成瘾严重程度指数和风险行为问卷)。对42名HIV阴性的注射吸毒者进行了前瞻性研究。中位年龄为42.5岁(范围18 - 61岁),42人中有28人(67%)为男性,注射中位时长为19.0年(范围0 - 43年)。分别在37名(88%)和31名(71%)参与者中检测到丙型肝炎病毒(HCV)和乙型肝炎病毒(HBV)抗体。23名(55%)参与者报告使用多种毒品;10名(24%)使用安非他命,9名(21%)使用海洛因。从成瘾严重程度指数数据中,我们未能发现任何与共用针头(n = 26/42,61%)或共用毒品混合物/过滤器(n = 25/42,59%)相关的具有统计学意义的因素。在26名共用针头的参与者中,19名(73%)也共用毒品混合物/过滤器。在这26名注射吸毒者中,7人与伴侣共用针头,11人与熟人共用,3人与陌生人共用,5人与各类人都共用。总之,研究组在血源性感染方面针对不同人群以及他们所接触的对象表现出不同的风险行为。这表明注射吸毒者可能会从关于感染HIV、HCV和HBV风险的个性化咨询中受益。